{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:54:58Z","timestamp":1781636098321,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although KIT mutations hold significant prognostic value in acute myeloid leukemia (AML), their impact on selecting first-line treatment remains unclear. This retrospective study of 222 newly diagnosed AML patients therefore compared the efficacy of venetoclax plus azacitidine (VA) versus intensive chemotherapy (IC) in KIT-mutated AML, while also exploring the prognostic implications of KIT mutation subtypes and their role in predicting VA response. Among patients with KIT mutations, IC was superior to VA, yielding significantly longer median event-free survival (EFS) (14.5 vs. 2.4 months,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.011) and overall survival (OS) (not reached vs. 9.8 months,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001), and a higher complete remission (CR) rate (80.0% vs. 17.6%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Exon 17 mutations were associated with significantly shorter EFS relative to other KIT mutations (7.3 vs. 18.8 months;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.046). Moreover, among all VA-treated patients, KIT mutation was an independent adverse prognostic factor for both EFS (HR\u2009=\u20093.25,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) and OS (HR\u2009=\u20093.31,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001). This study demonstrates the potential superiority of IC over VA in KIT-mutated AML and identifies KIT mutation as an important biomarker of resistance to venetoclax-based therapy, providing valuable guidance for first-line treatment decisions.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-06841-4","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T07:46:00Z","timestamp":1771227960000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Superior response and survival of intensive chemotherapy over venetoclax plus azacitidine in newly diagnosed KIT-mutated acute myeloid leukemia"],"prefix":"10.1007","volume":"105","author":[{"given":"Qingli","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minran","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"6841_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"6841_CR2","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1038\/s41375-018-0129-6","volume":"32","author":"P Paschka","year":"2018","unstructured":"Paschka P, Schlenk RF, Weber D et al (2018) Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia\u2014results of the AMLSG 11\u2009\u2013\u200908 trial. Leukemia 32:1621\u20131630. https:\/\/doi.org\/10.1038\/s41375-018-0129-6","journal-title":"Leukemia"},{"key":"6841_CR3","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/leu.2013.186","volume":"27","author":"C Allen","year":"2013","unstructured":"Allen C, Hills RK, Lamb K et al (2013) The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia 27:1891\u20131901. https:\/\/doi.org\/10.1038\/leu.2013.186","journal-title":"Leukemia"},{"key":"6841_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V et al (2019) Venetoclax combined with decitabine or Azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133:7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752","journal-title":"Blood"},{"key":"6841_CR5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.26039","volume":"96","author":"DA Pollyea","year":"2021","unstructured":"Pollyea DA, Pratz K, Letai A et al (2021) Venetoclax with Azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study. Am J Hematol 96:208\u2013217. https:\/\/doi.org\/10.1002\/ajh.26039","journal-title":"Am J Hematol"},{"key":"6841_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"6841_CR7","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1182\/blood-2005-09-3640","volume":"107","author":"R Cairoli","year":"2006","unstructured":"Cairoli R (2006) Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 107:3463\u20133468. https:\/\/doi.org\/10.1182\/blood-2005-09-3640","journal-title":"Blood"},{"key":"6841_CR8","doi-asserted-by":"publisher","first-page":"e0146614","DOI":"10.1371\/journal.pone.0146614","volume":"11","author":"W Chen","year":"2016","unstructured":"Chen W, Xie H, Wang H et al (2016) Prognostic significance of KIT mutations in Core-Binding factor acute myeloid leukemia: A systematic review and Meta-Analysis. PLoS ONE 11:e0146614. https:\/\/doi.org\/10.1371\/journal.pone.0146614","journal-title":"PLoS ONE"},{"key":"6841_CR9","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1182\/blood-2005-04-1466","volume":"107","author":"S Schnittger","year":"2006","unstructured":"Schnittger S, Kohl TM, Haferlach T et al (2006) KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 107:1791\u20131799. https:\/\/doi.org\/10.1182\/blood-2005-04-1466","journal-title":"Blood"},{"key":"6841_CR10","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.3390\/ijms231911393","volume":"23","author":"C Yang","year":"2022","unstructured":"Yang C, Gu Y, Ge Z, Song C (2022) Targeting EZH2 promotes chemosensitivity of BCL-2 inhibitor through suppressing PI3K and c-KIT signaling in acute myeloid leukemia. IJMS 23:11393. https:\/\/doi.org\/10.3390\/ijms231911393","journal-title":"IJMS"},{"key":"6841_CR11","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1200\/JCO.2006.06.9500","volume":"24","author":"P Paschka","year":"2006","unstructured":"Paschka P, Marcucci G, Ruppert AS et al (2006) Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with Inv (16) and t (8;21): A cancer and leukemia group B study. JCO 24:3904\u20133911. https:\/\/doi.org\/10.1200\/JCO.2006.06.9500","journal-title":"JCO"},{"key":"6841_CR12","doi-asserted-by":"publisher","unstructured":"Lazarus H, Miller M (2016) Midostaurin: an emerging treatment for acute myeloid leukemia patients. JBM 73. https:\/\/doi.org\/10.2147\/JBM.S100283","DOI":"10.2147\/JBM.S100283"},{"key":"6841_CR13","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","volume":"92","author":"J Lennartsson","year":"2012","unstructured":"Lennartsson J, R\u00f6nnstrand L (2012) Stem cell factor Receptor\/c-Kit: from basic science to clinical implications. Physiol Rev 92:1619\u20131649. https:\/\/doi.org\/10.1152\/physrev.00046.2011","journal-title":"Physiol Rev"},{"key":"6841_CR14","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/leu.2011.104","volume":"25","author":"S Wakita","year":"2011","unstructured":"Wakita S, Yamaguchi H, Miyake K et al (2011) Importance of c-kit mutation detection method sensitivity in prognostic analyses of t (8;21) (q22; q22) acute myeloid leukemia. Leukemia 25:1423\u20131432. https:\/\/doi.org\/10.1038\/leu.2011.104","journal-title":"Leukemia"},{"key":"6841_CR15","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1007\/s00018-004-4189-6","volume":"61","author":"L R\u00f6nnstrand","year":"2004","unstructured":"R\u00f6nnstrand L (2004) Signal transduction via the stem cell factor receptor\/c-Kit. CMLS Cell Mol Life Sci 61:2535\u20132548. https:\/\/doi.org\/10.1007\/s00018-004-4189-6","journal-title":"CMLS Cell Mol Life Sci"},{"key":"6841_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1172\/JCI9940","volume":"107","author":"PK Epling-Burnette","year":"2001","unstructured":"Epling-Burnette PK, Liu JH, Catlett-Falcone R et al (2001) Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107:351\u2013362. https:\/\/doi.org\/10.1172\/JCI9940","journal-title":"J Clin Invest"},{"key":"6841_CR17","doi-asserted-by":"publisher","first-page":"10853","DOI":"10.1073\/pnas.0804821105","volume":"105","author":"JR Mills","year":"2008","unstructured":"Mills JR, Hippo Y, Robert F et al (2008) mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA 105:10853\u201310858. https:\/\/doi.org\/10.1073\/pnas.0804821105","journal-title":"Proc Natl Acad Sci USA"},{"key":"6841_CR18","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan R, Hogdal LJ, Benito JM et al (2014) Selective BCL-2 Inhibition by ABT-199 causes On-Target cell death in acute myeloid leukemia. Cancer Discov 4:362\u2013375. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0609","journal-title":"Cancer Discov"},{"key":"6841_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1101\/gad.182980.111","volume":"26","author":"SP Glaser","year":"2012","unstructured":"Glaser SP, Lee EF, Trounson E et al (2012) Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 26:120\u2013125. https:\/\/doi.org\/10.1101\/gad.182980.111","journal-title":"Genes Dev"},{"key":"6841_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s12885-017-3383-5","volume":"17","author":"SK Tahir","year":"2017","unstructured":"Tahir SK, Smith ML, Hessler P et al (2017) Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer 17:399. https:\/\/doi.org\/10.1186\/s12885-017-3383-5","journal-title":"BMC Cancer"},{"key":"6841_CR21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","volume":"12","author":"DJ Goff","year":"2013","unstructured":"Goff DJ, Recart AC, Sadarangani A et al (2013) A Pan-BCL2 inhibitor renders Bone-Marrow-Resident human leukemia stem cells sensitive to tyrosine kinase Inhibition. Cell Stem Cell 12:316\u2013328. https:\/\/doi.org\/10.1016\/j.stem.2012.12.011","journal-title":"Cell Stem Cell"},{"key":"6841_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.tcb.2012.08.011","volume":"23","author":"RM Perciavalle","year":"2013","unstructured":"Perciavalle RM, Opferman JT (2013) Delving deeper: MCL-1\u2019s contributions to normal and cancer biology. Trends Cell Biol 23:22\u201329. https:\/\/doi.org\/10.1016\/j.tcb.2012.08.011","journal-title":"Trends Cell Biol"},{"key":"6841_CR23","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1182\/blood-2009-07-233304","volume":"115","author":"D Yecies","year":"2010","unstructured":"Yecies D, Carlson NE, Deng J, Letai A (2010) Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 115:3304\u20133313. https:\/\/doi.org\/10.1182\/blood-2009-07-233304","journal-title":"Blood"},{"key":"6841_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3722","volume":"15","author":"PE Czabotar","year":"2014","unstructured":"Czabotar PE, Lessene G, Strasser A, Adams JM (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15:49\u201363. https:\/\/doi.org\/10.1038\/nrm3722","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6841_CR25","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1182\/blood-2006-07-032714","volume":"109","author":"KJ Aichberger","year":"2007","unstructured":"Aichberger KJ, Mayerhofer M, Gleixner KV et al (2007) Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: Inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood 109:3031\u20133041. https:\/\/doi.org\/10.1182\/blood-2006-07-032714","journal-title":"Blood"},{"key":"6841_CR26","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1084\/jem.20050807","volume":"202","author":"JP Zappulla","year":"2005","unstructured":"Zappulla JP, Dubreuil P, Desbois S et al (2005) Mastocytosis in mice expressing human kit receptor with the activating Asp816Val mutation. J Exp Med 202:1635\u20131641. https:\/\/doi.org\/10.1084\/jem.20050807","journal-title":"J Exp Med"},{"key":"6841_CR27","doi-asserted-by":"publisher","first-page":"eaao1690","DOI":"10.1126\/scitranslmed.aao1690","volume":"9","author":"EK Evans","year":"2017","unstructured":"Evans EK, Gardino AK, Kim JL et al (2017) A precision therapy against cancers driven by KIT\/PDGFRA mutations. Sci Transl Med 9:eaao1690. https:\/\/doi.org\/10.1126\/scitranslmed.aao1690","journal-title":"Sci Transl Med"},{"key":"6841_CR28","doi-asserted-by":"publisher","first-page":"31461","DOI":"10.1074\/jbc.C300186200","volume":"278","author":"CD Mol","year":"2003","unstructured":"Mol CD, Lim KB, Sridhar V et al (2003) Structure of a c-Kit product complex reveals the basis for kinase transactivation. J Biol Chem 278:31461\u201331464. https:\/\/doi.org\/10.1074\/jbc.C300186200","journal-title":"J Biol Chem"},{"key":"6841_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jmgm.2004.04.003","volume":"23","author":"R Foster","year":"2004","unstructured":"Foster R, Griffith R, Ferrao P, Ashman L (2004) Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. J Mol Graph Model 23:139\u2013152. https:\/\/doi.org\/10.1016\/j.jmgm.2004.04.003","journal-title":"J Mol Graph Model"},{"key":"6841_CR30","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","volume":"106","author":"JD Growney","year":"2005","unstructured":"Growney JD, Clark JJ, Adelsperger J et al (2005) Activation mutations of human c-KIT resistant to Imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106:721\u2013724. https:\/\/doi.org\/10.1182\/blood-2004-12-4617","journal-title":"Blood"},{"key":"6841_CR31","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/sj.leu.2404188","volume":"20","author":"N Boissel","year":"2006","unstructured":"Boissel N, Leroy H, Brethon B et al (2006) Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 20:965\u2013970. https:\/\/doi.org\/10.1038\/sj.leu.2404188","journal-title":"Leukemia"},{"key":"6841_CR32","doi-asserted-by":"publisher","first-page":"104770","DOI":"10.1016\/j.critrevonc.2025.104770","volume":"212","author":"A Javidan","year":"2025","unstructured":"Javidan A, Azarboo A, Jalali S et al (2025) Secondary mutational and cytogenetic alterations in core binding factor \u2013 Acute myeloid leukemia (CBF-AML): A systematic review and meta-analysis. Crit Rev Oncol\/Hematol 212:104770. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104770","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"6841_CR33","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"PD Kottaridis","year":"2001","unstructured":"Kottaridis PD, Gale RE, Frew ME et al (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the united Kingdom medical research Council AML 10 and 12 trials. Blood 98:1752\u20131759. https:\/\/doi.org\/10.1182\/blood.V98.6.1752","journal-title":"Blood"},{"key":"6841_CR34","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/hon.3015","volume":"40","author":"J Wang","year":"2022","unstructured":"Wang J, Dao F, Wang Y et al (2022) Combination of KIT and FLT3- ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv (16) acute myeloid leukemia in first complete remission. Hematol Oncol 40:724\u2013733. https:\/\/doi.org\/10.1002\/hon.3015","journal-title":"Hematol Oncol"},{"key":"6841_CR35","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1182\/blood.2021011582","volume":"138","author":"K Lv","year":"2021","unstructured":"Lv K, Ren J-G, Han X et al (2021) Depalmitoylation rewires FLT3-ITD signaling and exacerbates leukemia progression. Blood 138:2244\u20132255. https:\/\/doi.org\/10.1182\/blood.2021011582","journal-title":"Blood"},{"key":"6841_CR36","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41409-023-01973-x","volume":"58","author":"J Kong","year":"2023","unstructured":"Kong J, Zheng F-M, Wang Z-D et al (2023) Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl 58:777\u2013783. https:\/\/doi.org\/10.1038\/s41409-023-01973-x","journal-title":"Bone Marrow Transpl"},{"key":"6841_CR37","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1080\/10428194.2022.2064994","volume":"63","author":"S Xue","year":"2022","unstructured":"Xue S, Huang W, Liu F et al (2022) Rapid response to avapritinib of acute myeloid leukemia with t (8;21) and KIT mutation relapse post allo-HSCT. Leuk Lymphoma 63:2247\u20132250. https:\/\/doi.org\/10.1080\/10428194.2022.2064994","journal-title":"Leuk Lymphoma"},{"key":"6841_CR38","doi-asserted-by":"publisher","first-page":"e30898","DOI":"10.1002\/pbc.30898","volume":"71","author":"IN Sheikh","year":"2024","unstructured":"Sheikh IN, AlQahtani S, Yin CC et al (2024) KIT -mutated pediatric core\u2010binding factor systemic mastocytosis\u2010acute myeloid leukemia treated with avapritinib and decitabine. Pediatr Blood Cancer 71:e30898. https:\/\/doi.org\/10.1002\/pbc.30898","journal-title":"Pediatr Blood Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06841-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06841-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06841-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:18:37Z","timestamp":1781633917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06841-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6841"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06841-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8030948\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Qilu Hospital of Shandong University (KYLL-202502-054), with a waiver for informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}